Gilead Licenses Boehringer Ingelheim’s NCINI Inhibitors for HIV
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 10 (Table of Contents)
Published: 31 Oct-2011
DOI: 10.3833/pdr.v2011.i10.1590 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Boehringer Ingelheim has granted Gilead Sciences exclusive worldwide rights for the research, development and commercialisation of its novel non-catalytic site integrase inhibitors (NCINIs) for HIV, including the lead compound BI-224436, which has completed a Phase Ia dose escalation study in healthy volunteers...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS